State Key Laboratory of Southwestern Chinese Medicine Resources, Pharmacy College of Chengdu University of Traditional Chinese Medicine, Chengdu 611137, Sichuan Province, China.
State Key Laboratory of Southwestern Chinese Medicine Resources, Pharmacy College of Chengdu University of Traditional Chinese Medicine, Chengdu 611137, Sichuan Province, China.
Int J Biol Macromol. 2023 Jul 31;244:124822. doi: 10.1016/j.ijbiomac.2023.124822. Epub 2023 May 29.
The polysaccharides (FP) extracted from the lateral roots of Aconitum carmichaelii Debx. (Fuzi) are natural compounds, which have effective therapy for rheumatoid arthritis (RA). Methotrexate (MTX) is the first-line drug for RA, but its application is greatly limited to the toxicity in liver and kidney and drug resistance. In this study, an attempt is made to apply oxidized FP (OFP) as a polymer carrier based on intra-articular delivery system loaded MTX. The FP could be modified and used as comprehensive gel carriers with biocompatibility and degradability for therapy of RA. Firstly, OFP-chitosan-poloxamer 407 in situ gel (OFP-CS-F407-MTX gel) was prepared by natural non-toxic cross-linking agents. Physicochemical characterization was performed by using H NMR and FTIR spectroscopic techniques to assess the successful functionalization of OFP. TGA, SEM and rheological experiment of OFP-CS-F407-MTX gel were investigated. Notably, we loaded MTX into OFP-CS-F407-MTX gel which had remarkable therapeutic efficacy and biosafety for RA. Therefore, OFP-CS-F407-MTX in situ gel delivery system can potentially reduce systemic toxicity and irritation of oral administration of MTX but hold a controlled release of drug for a long period of time.
从乌头(Fuzi)侧根中提取的多糖(FP)是天然化合物,对类风湿关节炎(RA)有有效治疗作用。甲氨蝶呤(MTX)是 RA 的一线药物,但由于其在肝脏和肾脏的毒性以及耐药性,其应用受到极大限制。本研究尝试将氧化 FP(OFP)作为载体制备基于关节内递药系统的负载 MTX 的聚合物载体。FP 可经修饰后用作具有生物相容性和可降解性的综合凝胶载体,用于 RA 的治疗。首先,通过天然无毒交联剂制备 OFP-壳聚糖-泊洛沙姆 407 原位凝胶(OFP-CS-F407-MTX 凝胶)。采用 H NMR 和 FTIR 光谱技术进行物理化学特性分析,以评估 OFP 成功的功能化。对 OFP-CS-F407-MTX 凝胶进行 TGA、SEM 和流变学实验研究。值得注意的是,我们将 MTX 载入 OFP-CS-F407-MTX 凝胶中,该凝胶对 RA 具有显著的治疗效果和生物安全性。因此,OFP-CS-F407-MTX 原位凝胶递药系统可降低 MTX 口服给药的全身毒性和刺激性,但能长时间控制药物释放。